Alectinib

- CAS No.
- 1256580-46-7
- Chemical Name:
- Alectinib
- Synonyms
- Alecensa;Alecitinib;Alectinib (CH5424802);AF-802;CS-217;canna*;RG-7853;alectinb;Aletinib;Alectinib
- CBNumber:
- CB62534680
- Molecular Formula:
- C30H34N4O2
- Molecular Weight:
- 482.62
- MOL File:
- 1256580-46-7.mol
- Modify Date:
- 2024/11/19 20:33:22
Melting point | 274-276°C |
---|---|
Boiling point | 722.5±60.0 °C(Predicted) |
Density | 1.28 |
storage temp. | -20° |
solubility | Soluble in DMSO (up to 5 mg/ml with warming). |
form | solid |
pka | 13.70±0.40(Predicted) |
color | White |
Stability | Stable for 1 year from date of purchase as supplied. Solutions are not stable and should be prepared fresh daily. |
SAFETY
Risk and Safety Statements
Symbol(GHS) | ![]() GHS08 |
---|---|
Signal word | Warning |
Hazard statements | H361-H341-H373 |
Precautionary statements | P201-P202-P281-P308+P313-P405-P501-P201-P202-P281-P308+P313-P405-P501-P260-P314-P501 |
HS Code | 2934999090 |
Alectinib Chemical Properties,Uses,Production
Description
Alectinib is another selective ALK inhibitor that is able to overcome resistance mutations from prior crizotinib exposure [38].
Chemical Properties
White to Off-White Solid
Indications
Alectinib (Alecensa(R), Roche) was approved first in Japan in 2014 and then by US FDA in 2015 as a second-generation ALK inhibitor for NSCLC treatment on patients who have progressed or do not tolerate crizotinib. Developed through a structure-based drug design approach, alectinib is a benzocarbazolone derivative that has shown potent inhibitory activity against ALK (IC50 value of 1.9 nM) and gatekeeper mutant L1196M ALK (IC50 value of 1.6 nM). Alectinib is effective with crizotinib-resistant ALK mutations on L1196M, F1174L, R1275Q, and C1156Y. In addition, an array of small-molecule inhibitors are currently being evaluated by several clinical trials for ALK-driven tumors.
Definition
ChEBI: An organic heterotetracyclic compound that is 6,6-dimethyl-5,6-dihydro-11H-benzo[b]carbazol-11-one carrying additional cyano, 4-(morpholin-4-yl)piperidin-1-yl and ethyl substituents at positions 3, 8 and 9 respectively. Used (as the hydr chloride salt) for the treatment of patients with anaplastic lymphoma kinase-positive, metastatic non-small cell lung cancer.
brand name
Alecensa?
General Description
Class: receptor tyrosine kinase; Treatment: NSCLC; Oral bioavailability = 37%; Elimination half-life = 33 h; Protein binding = >99%
target
Primary targets: ALK (IC50 = 1.9 nM)/RET (IC50 = 4.8 nM)
Alectinib Preparation Products And Raw materials
Raw materials
1of2
chevron_rightPreparation Products
Supplier | Tel | Country | ProdList | Advantage | Inquiry |
---|---|---|---|---|---|
AVD pharmaceuticals Pvt Ltd | +919860835260 | Pune, India | 102 | 58 | Inquiry |
Dr. Reddy's Laboratories Ltd | +91-4049002900 +91-4049002900 | Hyderabad, India | 165 | 58 | Inquiry |
Aspen Biopharma Labs Pvt Ltd | +91-9248058660 +91-9248058662 | Telangana, India | 234 | 58 | Inquiry |
CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6257 | 58 | Inquiry |
A.J Chemicals | 91-9810153283 | New Delhi, India | 6100 | 58 | Inquiry |
Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6739 | 58 | Inquiry |
SynZeal Research Pvt Ltd | +1 226-802-2078 | Gujarat, India | 6514 | 58 | Inquiry |
Pharma Affiliates | 172-5066494 | Haryana, India | 6754 | 58 | Inquiry |
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. | +86-18600796368 +86-18600796368 | China | 485 | 58 | Inquiry |
Capot Chemical Co.,Ltd. | +86-(0)57185586718 +86-13336195806 | China | 29730 | 60 | Inquiry |
Related articles
- What is Alectinib?
- Alectinib (trade name Alecensa) is a new type of highly selective ALK-TKI, which was approved by the US FDA on December 11, 20....
- Dec 26,2019
1256580-46-7(Alectinib)Related Search:
1of4
chevron_right